How to 'drug' our way out of the metabolic research models crisis (or not): the [PMID: 38664050] Laboratory literature summary: How to 'drug' our way out of the metabolic research models crisis (or not): the roll-out of semaglutide
Heart failure therapy by GLP-1RAs Although a meta-analysis of large-scale clinical trials suggested that GLP-1RAs reduce heart failure hospitalizations (HHF) by approximately 10% in patients with diabetes at high cardiovascular risk [22, 23], the treatment effects on the risk of HHF in individual trials other than AMPLITUDE-O were not significant (Tables 1, 2)
Since Wegovy (semaglutide) is used for long-term weight management and reducing heart disease risks in obese or overweight adults and children aged 12 and older, understanding these side effects is essential
At Set Point Medical Weight Loss Clinic, we also offer medical weight management programs for continuous support and guidance
This could include specialized infant formulas for babies with allergies or metabolic disorders, or nutritional supplements for patients with specific medical conditions
Short-acting agents slow down the stomach more than long-acting ones, though both types affect how we digest food